Dividend Growth Portfolio (GBP) October 2017

Strategy & Objective

The Dividend Growth Portfolio is a diversified portfolio (not a fund) of global equities, which we believe to be well positioned to outperform the wider equity market over the longer term. The portfolio has a bias towards developed market, large capitalisation stocks.

Portfolio Performance (GBP)^{1,2}

| | | | | | Annua | lised |
|---------------------------|------|---------|-------------------------------|--------|-----------------|--------------|
| Return (%) | YTD | 1 Month | 3 Month | 1 Year | 3 Years | S. Inception |
| Dividend Growth Portfolio | 2.0 | 0.0 | 0.5 | 7.2 | 15.3 | 15.2 |
| MSCI World | 9.9 | 2.8 | 3.7 | 13.1 | 15.1 | 15.7 |
| Relative | -7.9 | -2.8 | -3.2 | -5.9 | 0.2 | -0.5 |
| Risk (%) | | | Largest Drawdown Volatility (| | ty (Annualised) | |
| Dividend Growth Portfolio | | | | 11.2 | | 11.3 |
| MSCI World | | | | 16.2 | | 11.8 |

Market Commentary

October was a positive month for global equity markets. In the US, the DJIA rose 4.4% as both the Senate and the House approved a fiscal budget providing scope for future tax reform legislation. Secession was the theme across headlines in Europe, with the Spanish national government dissolving the Catalan Parliament and Catalonian leader Puigdemont announcing independence. The UK's Brexit Secretary David Davis admitted that any deal will likely favour the EU, as proposed transition talks were rejected by leading EU states until a divorce deal is agreed. Yet the Euro STOXX 50 rose 2.3% and FTSE 100 returned 1.8% during the period. The major bond markets saw some divergence with 10 year rates in the US rising to 2.38%, whilst UK and German 10 year rates fell to 1.33%, and 0.36% respectively.


Key Contributors to Return

Microsoft's shares increased by 11.7% after strong first quarter results, beating consensus estimates at both the revenue and profit level. BP's shares increased by 6.9%, helped by positive third quarter results in which they beat consensus expectations and announced a share repurchase plan.

Key Detractors from Return

CVS Health's shares declined by 15.3%, reacting negatively to continued rumours that Amazon are looking to enter the pharmaceutical retail market. Nielsen's shares declined by 10.6%, suffering from negative commentary on the outlook for the Buy segment in developed markets.

Performance Since Inception (28/12/2012)²



Dividend Growth Portfolio (GBP) October 2017



Sample Portfolio Statistics²

| | Current Price | Trailing 12 Month P/E | 12 Month Forward P/E | Dividend Yield |
|-------------------------|------------------|--------------------------|-------------------------|-------------------|
| GlaxoSmithKline plc | 1358p | 13.8x | 12.3x | 5.9% |
| Nielsen Holdings plc | \$37.1 | 23.1x | 13.4x | 3.7% |
| Wells Fargo & Co | \$56.1 | 13.7x | 13.2x | 2.8% |
| Total Portfolio Average | | 17.8x | 14.6x | 3.7% |
| MSCI World | | 21.0x | 16.8x | 2.4% |

Currency Allocation

Telecommunication Services AUD Information Technology Industrials Health Care GBP Financials Energy **Consumer Staples** USD **Consumer Discretionary** 0% 10% 20% 30% 0% 20% 40% 60%

Sector Allocation

Investment Philosophy

Credo's investment philosophy is based on the following tenets:

- We believe wealth is created and preserved by following a patient and disciplined investment strategy that is focused on the long-term.
- We follow a value-based approach to investing.
- We strive to identify matters of strategic importance and focus on methodologies that have proven to be robust through a variety of market cycles, rather than fixating on short-term news-flow and forecasts.
- · We aim to minimise turnover in our portfolios and apply our minds when considering transaction size in an attempt to limit transaction costs.
- · We view risk as permanent losses of capital and not in terms of short-term volatility.

Important Notice

This document has been created for information purposes only and has been compiled from sources believed to be reliable. None of Credo, its directors, officers or employees accepts liability for any loss arising from the use hereof or reliance hereon or for any act or omission by any such person, or makes any representations as to its accuracy and completeness. This document does not constitute an offer or solicitation to invest, it is not advice or a personal recommendation nor does it take into account the particular investment objectives, financial situation or needs of individual clients and if you are interested in any of the information contained herein, it is recommended that you seek advice concerning suitability from your investment advisor. Investors are warned that past performance is not necessarily a guide to future performance, income is not guaranteed, share prices may go up or down and you may not get back the original capital invested. The value of your investment may also rise or fall due to changes in tax rates and rates of exchange if different to the currency in which you measure your wealth. Credo Capital plc is authorised and regulated by the Financial Conduct Authority and is an Authorised Financial Services Provider; FSP No: 9757.

(1) Performance figures are based on a notional portfolio, denominated in pound sterling, designed to track the holdings of the Credo Dividend Growth Portfolio. Portfolio incorporates all additions and removals, rebalancing all holding to a 5% weighting in the process. Portfolio may not be fully invested at a point in time and therefore can hold a portion of assets in cash, which is assumed to be held in the relevant reporting currency of the portfolio. Portfolio and Benchmark performance is calculated before any fees and includes reinvested dividends net of withholding tax.

(2) Source: Bloomberg pricing as of 31/10/2017 close. All portfolio performance is calculated using Bloomberg PORT, rounded to 1 decimal place.

Dividend Growth Portfolio (USD) October 2017



Strategy & Objective

The Dividend Growth Portfolio is a diversified portfolio (not a fund) of global equities, which we believe to be well positioned to outperform the wider equity market over the longer term. The portfolio has a bias towards developed market, large capitalisation stocks.

Portfolio Performance (USD)^{1,2}

| | | | | | Annua | lised |
|---------------------------|------|---------|---------|--------|---------|--------------|
| Return (%) | YTD | 1 Month | 3 Month | 1 Year | 3 Years | S. Inception |
| Dividend Growth Portfolio | 9.6 | -0.9 | 1.1 | 16.3 | 8.6 | 10.9 |
| MSCI World | 18.2 | 1.9 | 4.3 | 22.8 | 8.1 | 11.3 |
| Relative | -8.6 | -2.8 | -3.2 | -6.5 | 0.5 | -0.4 |

| Volatility (Annualised) | Largest Drawdown | Risk (%) | |
|-------------------------|------------------|---------------------------|--|
| 5 11.0 | 11.6 | Dividend Growth Portfolio | |
| 10.5 | 17.9 | MSCI World | |
| .9 | 17 | MSCI World | |

Market Commentary

October was a positive month for global equity markets. In the US, the DJIA rose 4.4% as both the Senate and the House approved a fiscal budget providing scope for future tax reform legislation. Secession was the theme across headlines in Europe, with the Spanish national government dissolving the Catalan Parliament and Catalonian leader Puigdemont announcing independence. The UK's Brexit Secretary David Davis admitted that any deal will likely favour the EU, as proposed transition talks were rejected by leading EU states until a divorce deal is agreed. Yet the Euro STOXX 50 rose 2.3% and FTSE 100 returned 1.8% during the period. The major bond markets saw some divergence with 10 year rates in the US rising to 2.38%, whilst UK and German 10 year rates fell to 1.33%, and 0.36% respectively.


Key Contributors to Return

Microsoft's shares increased by 11.7% after strong first quarter results, beating consensus estimates at both the revenue and profit level. BP's shares increased by 6.9%, helped by positive third quarter results in which they beat consensus expectations and announced a share repurchase plan.

Key Detractors from Return

CVS Health's shares declined by 15.3%, reacting negatively to continued rumours that Amazon are looking to enter the pharmaceutical retail market. Nielsen's shares declined by 10.6%, suffering from negative commentary on the outlook for the Buy segment in developed markets.

Performance Since Inception (28/12/2012)²



Dividend Growth Portfolio (USD) October 2017



Sample Portfolio Statistics²

| | Current Price | Trailing 12 Month P/E | 12 Month Forward P/E | Dividend Yield |
|-------------------------|------------------|--------------------------|-------------------------|-------------------|
| GlaxoSmithKline plc | 1358p | 13.8x | 12.3x | 5.9% |
| Nielsen Holdings plc | \$37.1 | 23.1x | 13.4x | 3.7% |
| Wells Fargo & Co | \$56.1 | 13.7x | 13.2x | 2.8% |
| Total Portfolio Average | | 17.8x | 14.6x | 3.7% |
| MSCI World | | 21.0x | 16.8x | 2.4% |

Sector Allocation **Currency Allocation Telecommunication Services** AUD Information Technology Industrials Health Care GBP Financials Energy **Consumer Staples** USD Consumer Discretionary 0% 10% 20% 30% 0% 20% 40% 60%

Investment Philosophy

Credo's investment philosophy is based on the following tenets:

- · We believe wealth is created and preserved by following a patient and disciplined investment strategy that is focused on the long-term.
- We follow a value-based approach to investing.
- We strive to identify matters of strategic importance and focus on methodologies that have proven to be robust through a variety of market cycles, rather than fixating on short-term news-flow and forecasts.
- · We aim to minimise turnover in our portfolios and apply our minds when considering transaction size in an attempt to limit transaction costs.
- We view risk as permanent losses of capital and not in terms of short-term volatility.

Important Notice

This document has been created for information purposes only and has been compiled from sources believed to be reliable. None of Credo, its directors, officers or employees accepts liability for any loss arising from the use hereof or reliance hereon or for any act or omission by any such person, or makes any representations as to its accuracy and completeness. This document does not constitute an offer or solicitation to invest, it is not advice or a personal recommendation nor does it take into account the particular investment objectives, financial situation or needs of individual clients and if you are interested in any of the information contained herein, it is recommended that you seek advice concerning suitability from your investment advisor. Investors are warned that past performance is not necessarily a guide to future performance, income is not guaranteed, share prices may go up or down and you may not get back the original capital invested. The value of your investment may also rise or fall due to changes in tax rates and rates of exchange if different to the currency in which you measure your wealth. Credo Capital plc is authorised and regulated by the Financial Conduct Authority and is an Authorised Financial Services Provider; FSP No: 9757.

- (1) Performance figures are based on a notional portfolio, denominated in US dollar, designed to track the holdings of the Credo Dividend Growth Portfolio. Portfolio incorporates all additions and removals, rebalancing all holding to a 5% weighting in the process. Portfolio may not be fully invested at a point in time and therefore can hold a portion of assets in cash, which is assumed to be held in the relevant reporting currency of the portfolio. Portfolio and Benchmark performance is calculated before any fees and includes reinvested dividends net of withholding tax.
- (2) Source: Bloomberg pricing as of 31/10/2017 close. All portfolio performance is calculated using Bloomberg PORT, rounded to 1 decimal place.